Best Endovascular vs. best Surgical Therapy in patients with Critical Limb Ischemia (BEST-CLI) is a prospective, multicenter, randomized, open-label (two-arm), comparison to evaluate the effectiveness of best surgical to best endovascular revascularization in patients with CLI.
Dr. Alik Farber is a Professor of Surgery and Radiology at Boston University School of Medicine and the Chief of Vascular and Endovascular Surgery at Boston Medical Center.
Dr. Matthew Menard is an Associate Professor of Surgery at Harvard Medical School and is Co-Director of Endovascular Surgery and Program Director of the vascular surgery fellowship at Brigham and Women’s Hospital.
Topics Discussed
- History of the trial - mentors involved, interactions with the NIH
- Context of the literature - limitations of the BASIL trial
- Barriers to enrollment and strategies of successful institutions
- Choosing the endpoint of Major Adverse Limb Event (Male)-free survival
- Implications of cost-effectiveness component
- Impact of paclitaxel controversy on the trial
- Early lessons learned and much, much, more!!